COVID-19 Symptom Tracker
Other: No Intervention
Massachusetts General Hospital
Boston, Massachusetts, United States
King's College London
London, United Kingdom
Study Type : Observational
Estimated Enrollment : 10000000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: COVID-19 Symptom Tracker
Actual Study Start Date : March 23, 2020
Estimated Primary Completion Date : March 23, 2022
Estimated Study Completion Date : March 23, 2022
-=-=-=-=-
Recruiting (모집중)
Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19Device: oxyhydrogen
Device: Oxygen
First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-center, Randomized, Parallel-Controlled Clinical Trial of the Application of A Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19
Actual Study Start Date : February 15, 2020
Actual Primary Completion Date : February 21, 2020
Estimated Study Completion Date : August 1, 2020
-=-=-=-=-=-
Recruiting (모집중)
DAS181 for Severe COVID-19: Compassionate Use
Drug: DAS181
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 4 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: DAS181 for Severe COVID-19: Compassionate Use
Actual Study Start Date : March 6, 2020
Estimated Primary Completion Date : April 25, 2020
Estimated Study Completion Date : April 30, 2020
-=-=-=-=-=-
Recruiting (모집중)
Study of Open Label Losartan in COVID-19
Drug: Losartan
University of Kansas Medical Center
Kansas City, Kansas, United States
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 50 participantsIntervention Model: Single Group Assignment
Intervention Model Description: 50 patients with COVID-19 and respiratory failure who meet criteria and agree to participation in the study will be placed on losartan 25 mg daily on study day 0. If parameters are met the dose of losartan will be increased to 50 mg on study day 3. Patients and/or surrogate decision maker who do not give consent to treatment will be asked to allow collection of data from their medical record for use as a control group.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Phase 1 Trial of Losartan for Worsening Respiratory Illness in COVID-19
Actual Study Start Date : March 25, 2020
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : October 2020
-=-=-=-=-
Recruiting (모집중)
Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.Drug: TCM prescriptions
Huai'an fourth people's Hospital
Huaian, Jiangsu, China
Study Type : Observational
Estimated Enrollment : 340 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19 in Jiangsu Province
Actual Study Start Date : March 2, 2020
Estimated Primary Completion Date : May 2020
Estimated Study Completion Date : May 2020
-=-=-=-=
Recruiting (모집중)
A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19
Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells
Chongqing Public Health Medical Center
Chongqing, China
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19
Actual Study Start Date : March 21, 2020
Estimated Primary Completion Date : May 31, 2020
Estimated Study Completion Date : September 30, 2020
-=-=-=-=
Recruiting (모집중)
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19Drug: Sarilumab
Drug: Placebo
Regeneron Study Site
Los Angeles, California, United States
Regeneron Study Site
Sacramento, California, United States
Regeneron Study Site
Santa Monica, California, United States
(and 60 more...)
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19
Actual Study Start Date : March 18, 2020
Estimated Primary Completion Date : March 9, 2021
Estimated Study Completion Date : April 1, 2021
-=-=-=-=-
Recruiting (모집중)
Beat COVID-19 - Observational Trial
Beat COIVD, LLC
Chicago, Illinois, United States
Study Type : Observational
Estimated Enrollment : 100000 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: A Virtual Observational Protocol to Gain Longitudinal Data in Participants to Help Understand COVID-19 Spread and Disease Progression
Estimated Study Start Date : April 6, 2020
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : July 2021
-=-=-=-=-
Recruiting (모집중)
A Pilot Study of Sildenafil in COVID-19Drug: Sildenafil citrate tablets
Department and Institute of Infectious Disease
Wuhan, Hubei, China
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of Sildenafi in the Treatment of COVID-19
Actual Study Start Date : February 9, 2020
Actual Primary Completion Date : March 1, 2020
Estimated Study Completion Date : November 9, 2020
-=-=-=-=-
Recruiting (모집중)
Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis
Drug: Tocilizumab
University of Chicago Medicine
Chicago, Illinois, United States
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis
Estimated Study Start Date : April 2020
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : December 2020
-=-=-=-=-
Recruiting (모집중)
Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers
Drug: Hydroxychloroquine
Baylor University Medical Center
Dallas, Texas, United States
Study Type : nterventional (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation:Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose:Prevention
Official Title: A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures
Estimated Study Start Date : April 3, 2020
Estimated Primary Completion Date : July 30, 2020
Estimated Study Completion Date : July 30, 2020
-=-=-=-=-
Recruiting (모집중, 한국 임상)
Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)
Drug: Lopinavir/ritonavir
Drug: Hydroxychloroquine sulfate
Asan Medical Center, University of Ulsan College of Medicine
Seoul, Korea, Republic of
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Multicenter, open labelled, randomized clinical trial
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)
Actual Study Start Date : March 11, 2020
Estimated Primary Completion Date : May 2020
Estimated Study Completion Date : May 2020
-=-=-=-=-
Recruiting (모집중)
Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients
Biological: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)
Other: Intravenous saline injection (Placebo)
Renmin Hospital of Wuhan University (East Campus)
Wuhan, Hubei, China
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19：a Single-center, Prospective, Randomised Clinical Trial
Estimated Study Start Date : April 6, 2020
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : March 31, 2021
-=-=-=-=-
Recruiting (모집중)
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
Drug: Remdesivir
Drug: Standard of Care
Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue
Anaheim, California, United States
Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway
Downey, California, United States
Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave
Fontana, California, United States
(and 105 more...)
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 2400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19
Actual Study Start Date : March 6, 2020
Estimated Primary Completion Date : May 2020
Estimated Study Completion Date : May 2020
-=-=-=-=-
Recruiting (모집중)
COVID-19 in Patients With HIV
COVID-19
SARS-CoV-2
Other: No intervention
University of Missouri-Columbia
Columbia, Missouri, United States
Study Type : Observational [Patient Registry]
Estimated Enrollment : 500 participants
Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration: 1 Month
Official Title: Prospective Observational Study for Patients With HIV and Confirmed SARS-CoV-2
Estimated Study Start Date : April 1, 2020
Estimated Primary Completion Date : October 1, 2020
Estimated Study Completion Date : October 1, 2020
-=-=-=-=-
Recruiting (모집중)
Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic DiseaseDrug: Hydroxychloroquine
Drug: Placebo
University of Arizona
Tucson, Arizona, United States
UCSF Fresno
Fresno, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
(and 41 more...)
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 510 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.
Primary Purpose: Treatment
Official Title: Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease
Actual Study Start Date : April 2, 2020
Estimated Primary Completion Date : April 2021
Estimated Study Completion Date : July 2021
-=-=-=-=-
Recruiting (모집중 - 사이토카인 스톰)
Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19
Drug: Tocilizumab
Other: Standard of care
Procedure: Continuous renal replacement therapy
Tongji Hospital
Wuhan, Hubei, China
Study Type : Observational Estimated Enrollment :120 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: A Retrospective Study of Evaluating Safety and Efficacy of Tocilizumab Compared to Continuous Renal Replacement Therapy in Controlling CRS Triggered by COVID-19
Actual Study Start Date : February 20, 2020
Estimated Primary Completion Date : May 30, 2020
Estimated Study Completion Date : June 20, 2020
-=-=-=-=-
Recruiting (모집중)
Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus
2019 Novel Coronavirus Pneumonia
Biological: MSCs
Beijing 302 Military Hospital of China
Beijing, China
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With 2019 Novel Coronavirus
Actual Study Start Date : January 27, 2020
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2021
-=-=-=-=-
Recruiting (모집중)
Adaptive COVID-19 Treatment Trial (ACTT)Corona Virus Infection
Other: Placebo
Drug: Remdesivir
University of Alabama at Birmingham School of Medicine - Infectious Disease
Birmingham, Alabama, United States
University of California San Diego Health - Jacobs Medical Center
La Jolla, California, United States
University of California Los Angeles Medical Center - Westwood Clinic
Los Angeles, California, United States
(and 51 more...)
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 440 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
Actual Study Start Date : February 21, 2020
Estimated Primary Completion Date : April 1, 2023
Estimated Study Completion Date : April 1, 2023
-=-=-=-=-
Recruiting (모집중)
Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu
Pulmonary Fibrosis Due to 2019-nCoV
Drug: N-acetylcysteine+ Fuzheng Huayu Tablet
Drug: N-acetylcysteine+Placebo
Shuguang Hospital
Shanghai, Shanghai, China
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 136 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-Controlled, Multi-Center Study on the Efficacy and Safety of Fuzheng Huayu on Pulmonary Fibrosis Due to 2019-nCoV
Estimated Study Start Date : February 15, 2020
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2022